Evaluating the costs of adverse drug events in hospitalized patients: a systematic review.

IF 2.7 3区经济学 Q1 ECONOMICS

Health Economics Review Pub Date : 2024-02-08 DOI:10.1186/s13561-024-00481-y

Maxime Durand, Christel Castelli, Clarisse Roux-Marson, Jean-Marie Kinowski, Géraldine Leguelinel-Blache

{"title":"Evaluating the costs of adverse drug events in hospitalized patients: a systematic review.","authors":"Maxime Durand, Christel Castelli, Clarisse Roux-Marson, Jean-Marie Kinowski, Géraldine Leguelinel-Blache","doi":"10.1186/s13561-024-00481-y","DOIUrl":null,"url":null,"abstract":"Background: Adverse drug events (ADEs) are not only a safety and quality of care issue for patients, but also an economic issue with significant costs. Because they often occur during hospital stays, it is necessary to accurately quantify the costs of ADEs. This review aimed to investigate the methods to calculate these costs, and to characterize their nature.Methods: A systematic literature review was conducted to identify methods used to assess the cost of ADEs on Medline, Web of Science and Google Scholar. Original articles published from 2017 to 2022 in English and French were included. Economic evaluations were included if they concerned inpatients.Results: From 127 studies screened, 20 studies were analyzed. There was a high heterogeneity in nature of costs, methods used, values obtained, and time horizon chosen. A small number of studies considered non-medical (10%), indirect (20%) and opportunity costs (5%). Ten different methods for assessing the cost of ADEs have been reported and nine studies did not explain how they obtained their values.Conclusions: There is no consensus in the literature on how to assess the costs of ADEs, due to the heterogeneity of contexts and the choice of different economic perspectives. Our study adds a well-deserved overview of the existing literature that can be a solid lead for future studies and method implementation.Trial registration: PROSPERO registration CRD42023413071.","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"11"},"PeriodicalIF":2.7000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10851489/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Economics Review","FirstCategoryId":"96","ListUrlMain":"https://doi.org/10.1186/s13561-024-00481-y","RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Adverse drug events (ADEs) are not only a safety and quality of care issue for patients, but also an economic issue with significant costs. Because they often occur during hospital stays, it is necessary to accurately quantify the costs of ADEs. This review aimed to investigate the methods to calculate these costs, and to characterize their nature.

Methods: A systematic literature review was conducted to identify methods used to assess the cost of ADEs on Medline, Web of Science and Google Scholar. Original articles published from 2017 to 2022 in English and French were included. Economic evaluations were included if they concerned inpatients.

Results: From 127 studies screened, 20 studies were analyzed. There was a high heterogeneity in nature of costs, methods used, values obtained, and time horizon chosen. A small number of studies considered non-medical (10%), indirect (20%) and opportunity costs (5%). Ten different methods for assessing the cost of ADEs have been reported and nine studies did not explain how they obtained their values.

Conclusions: There is no consensus in the literature on how to assess the costs of ADEs, due to the heterogeneity of contexts and the choice of different economic perspectives. Our study adds a well-deserved overview of the existing literature that can be a solid lead for future studies and method implementation.

Trial registration: PROSPERO registration CRD42023413071.

查看原文本刊更多论文

评估住院患者药物不良事件的成本：系统综述。

背景：药物不良事件（ADEs）不仅关系到患者的安全和医疗质量，也是一个经济问题，需要花费大量成本。由于不良药物事件经常发生在住院期间，因此有必要准确量化不良药物事件的成本。本综述旨在研究计算这些成本的方法，并确定其性质：在 Medline、Web of Science 和 Google Scholar 上进行了系统的文献综述，以确定用于评估 ADE 成本的方法。收录了 2017 年至 2022 年发表的英文和法文原创文章。涉及住院患者的经济评估也被纳入其中：从筛选出的 127 项研究中，对 20 项研究进行了分析。在成本性质、使用的方法、获得的价值和选择的时间跨度方面存在很大的异质性。少数研究考虑了非医疗成本（10%）、间接成本（20%）和机会成本（5%）。据报道，评估 ADE 成本的方法有 10 种，其中有 9 项研究没有解释他们是如何获得成本值的：结论：由于背景的异质性和选择不同的经济学视角，文献中对如何评估 ADE 的成本没有达成共识。我们的研究对现有文献进行了应有的概述，为今后的研究和方法实施提供了坚实的基础：PROSPERO 注册号：CRD42023413071。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Health Economics Review Multiple-

CiteScore

3.90

自引率

4.20%

发文量

审稿时长

13 weeks

期刊介绍： Health Economics Review is an international high-quality journal covering all fields of Health Economics. A broad range of theoretical contributions, empirical studies and analyses of health policy with a health economic focus will be considered for publication. Its scope includes macro- and microeconomics of health care financing, health insurance and reimbursement as well as health economic evaluation, health services research and health policy analysis. Further research topics are the individual and institutional aspects of health care management and the growing importance of health care in developing countries.